Get the Stockscreener App
47.50
3.26%
1.50
After Hours:
47.00
-0.50
-1.05%
Qiagen Nv stock is traded at $47.50, with a volume of 1.22M.
It is up +3.26% in the last 24 hours and up +6.34% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$46.00
Open:
$47.38
24h Volume:
1.22M
Relative Volume:
1.44
Market Cap:
$10.56B
Revenue:
$1.97B
Net Income/Loss:
$92.93M
P/E Ratio:
116.82
EPS:
0.4066
Net Cash Flow:
$459.60M
1W Performance:
+4.24%
1M Performance:
+6.34%
6M Performance:
+14.32%
1Y Performance:
+2.06%
1-Day Range:
$47.21
$47.61
1-Week Range:
$45.10
$47.61
52-Week Range:
$39.03
$47.61
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
47.50 | 10.56B | 1.97B | 92.93M | 459.60M | 0.4066 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen (NYSE:QGEN) Hits New 1-Year HighHere's What Happened - MarketBeat
Qiagen stock hits 52-week high at $47.45 amid steady growth - Investing.com
Genetic Testing Market Projected To Witness Substantial Growth, 2025-2032: Eurofins Scientific, Illumina Inc., - EIN News
Cancer Biopsy Market Size is Expected to Reach USD 60.92 Billion by 2033, Growing at a CAGR of 7.81%: Straits Research - GlobeNewswire Inc.
QGEN Stock Might Rise Following Partnership With Genomics England - MSN
Strategic Collaborations Aid QGEN Stock Amid Competition - Yahoo Finance
Qiagen (NYSE:QGEN) Short Interest Update - MarketBeat
QIAGEN Finalizes $300 Million Synthetic Share Repurchase Plan - TipRanks
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million - Silicon Canals
QIAGEN Announces $300M Share Repurchase Plan with Reverse Stock Split, $1.26 Per Share Payout - StockTitan
Qiagen Announces BlackRock’s Significant Voting Rights in Recent AFM Disclosure - TipRanks
Qiagen N.V. Voting Rights Update: BlackRock’s Significant Stake Disclosed - TipRanks
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast - BioSpace
QIAGEN Sets Q4 2024 Earnings Release Date: Conference Call Details Announced - StockTitan
Qiage announces $300M buyback plan - MSN
Qiagen N : Ad hoc Announcement according to Art. 17 Market Abuse Regulation - Marketscreener.com
QIAGEN Announces $300 Million Synthetic Share Repurchase Plan - TipRanks
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples - Marketscreener.com
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase - BioSpace
New Product Offerings Support QIAGEN's Shares Amid Currency Woes - MSN
QIAGEN Unveils New $300M Share Buyback Plan, Accelerating $1B Shareholder Return Strategy - StockTitan
Qiagen Announces BlackRock’s Significant Stake in Company - TipRanks
Qiagen N.V.'s (NYSE:QGEN) Share Price Not Quite Adding Up - Simply Wall St
QGENQIAGEN N.V. Latest Stock News & Market Updates - StockTitan
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights from Biological Samples - Marketscreener.com
QIAGEN Doubles Digital PCR Capabilities: QIAcuity Now Analyzes 12 Targets Simultaneously - StockTitan
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care - DutchNews.nl
QIAGEN Secures FDA Clearance for Groundbreaking Rapid Gastrointestinal Test Panel - StockTitan
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Qiagen (NYSE:QGEN) Receives $51.50 Consensus Target Price from Brokerages - MarketBeat
BlackRock’s Significant Stake Announcement in Qiagen - TipRanks
QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content - sharewise
Qiagen (NYSE:QGEN) Given Equal Weight Rating at Morgan Stanley - MarketBeat
Qiagen stock downgrade: Morgan Stanley says outperformance may be capped By Investing.com - Investing.com South Africa
Tuberculosis Diagnostics Market Opportunities and Strategies to 2033, Key Companies Include Beckton, Dickinson and Co, Qiagen, F. Hoffmann-La Roche, bioMerieux, and Danaher - Yahoo Finance
Qiagen stock downgrade: Morgan Stanley says outperformance may be capped - Investing.com
Morgan Stanley Downgrades Qiagen NV (QGEN) to Equalweight - StreetInsider.com
JPMorgan Chase & Co. Raises Stock Position in Qiagen (NYSE:QGEN) - MarketBeat
Qiagen N.V. Discloses BlackRock’s Voting Rights Notification - TipRanks
Here's Why Qiagen (QGEN) is a Strong Momentum Stock - MSN
BlackRock Increases Voting Influence in Qiagen - TipRanks
Why Is Qiagen N.V. (QGEN) Among the Top CRISPR Stocks to Invest In? - Yahoo Finance
With 83% ownership of the shares, Qiagen N.V. (NYSE:QGEN) is heavily dominated by institutional owners - Simply Wall St
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):